<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2&amp;utm_source=Chrome&amp;ff=20240209170828&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;v=2.18.0&amp;fc=20230708114047
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2&amp;utm_source=Chrome&amp;ff=20240209170828&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;v=2.18.0&amp;fc=20230708114047" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0)</generator>
<language>en</language>
<lastbuilddate>Fri, 09 Feb 2024 22:08:29 +0000</lastbuilddate>
<pubDate>Fri, 09 Feb 2024 06:00:00 -0500</pubDate>
<ttl>120</ttl>
<item>
<title>Retraction of: Age-Induced Accumulation of Succinate Promotes Cardiac Fibrogenesis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38333982/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240209170828&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Feb 9. doi: 10.1161/RES.0000000000000663. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38333982/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240209170828&v=2.18.0">38333982</a> | DOI:<a href=https://doi.org/10.1161/RES.0000000000000663>10.1161/RES.0000000000000663</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38333982</guid>
<pubDate>Fri, 09 Feb 2024 06:00:00 -0500</pubDate>
<dc:date>2024-02-09</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Retraction of: Age-Induced Accumulation of Succinate Promotes Cardiac Fibrogenesis</dc:title>
<dc:identifier>pmid:38333982</dc:identifier>
<dc:identifier>doi:10.1161/RES.0000000000000663</dc:identifier>
</item>
<item>
<title>Clinical and Prognostic Implications of Right Ventricular Uptake on Bone Scintigraphy in Transthyretin Amyloid Cardiomyopathy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38328945/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240209170828&amp;v=2.18.0
      <description>CONCLUSIONS: Diffuse RV uptake of bone tracer on SPECT imaging is associated with poor outcomes in patients with ATTR-CM and is an independent prognostic marker at diagnosis.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Feb 8. doi: 10.1161/CIRCULATIONAHA.123.066524. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: The extent of myocardial bone tracer uptake with technetium pyrophosphate, hydroxymethylene diphosphonate, and 3,3-diphosphono-1,2-propanodicarboxylate in transthyretin amyloid cardiomyopathy (ATTR-CM) might reflect cardiac amyloid burden and be associated with outcome.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Consecutive patients with ATTR-CM who underwent diagnostic bone tracer scintigraphy with acquisition of whole-body planar and cardiac single-photon emission computed tomography (SPECT) images from the National Amyloidosis Centre and 4 Italian centers were included. Cardiac uptake was defined according to the Perugini classification: 0=absent cardiac uptake; 1=mild uptake less than bone; 2=moderate uptake equal to bone; and 3=high uptake greater than bone. Extent of right ventricular (RV) uptake was defined as focal (basal segment of the RV free wall only) or diffuse (extending beyond basal segment) on the basis of SPECT imaging. The primary outcome was all-cause mortality.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Among 1422 patients with ATTR-CM, RV uptake accompanying left ventricular uptake was identified by SPECT imaging in 100% of cases at diagnosis. Median follow-up in the whole cohort was 34 months (interquartile range, 21 to 50 months), and 494 patients died. By Kaplan-Meier analysis, diffuse RV uptake on SPECT imaging (n=936) was associated with higher all-cause mortality compared with focal (n=486) RV uptake (77.9% versus 22.1%; <i>P</i>&lt;0.001), whereas Perugini grade was not associated with survival (<i>P</i>=0.27 in grade 2 versus grade 3). On multivariable analysis, after adjustment for age at diagnosis (hazard ratio [HR], 1.03 [95% CI, 1.02-1.04]; <i>P</i>&lt;0.001), presence of the p.(V142I) TTR variant (HR, 1.42 [95% CI, 1.20-1.81]; <i>P</i>=0.004), National Amyloidosis Centre stage (each category, <i>P</i>&lt;0.001), stroke volume index (HR, 0.99 [95% CI, 0.97-0.99]; <i>P</i>=0.043), E/e' (HR, 1.02 [95% CI, 1.007-1.03]; <i>P</i>=0.004), right atrial area index (HR, 1.05 [95% CI, 1.02-1.08]; <i>P</i>=0.001), and left ventricular global longitudinal strain (HR, 1.06 [95% CI, 1.03-1.09]; <i>P</i>&lt;0.001), diffuse RV uptake on SPECT imaging (HR, 1.60 [95% CI, 1.26-2.04]; <i>P</i>&lt;0.001) remained an independent predictor of all-cause mortality. The prognostic value of diffuse RV uptake was maintained across each National Amyloidosis Centre stage and in both wild-type and hereditary ATTR-CM (<i>P</i>&lt;0.001 and <i>P</i>=0.02, respectively).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Diffuse RV uptake of bone tracer on SPECT imaging is associated with poor outcomes in patients with ATTR-CM and is an independent prognostic marker at diagnosis.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38328945/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240209170828&v=2.18.0">38328945</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.066524>10.1161/CIRCULATIONAHA.123.066524</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38328945</guid>
<pubDate>Thu, 08 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Aldostefano Porcari</dc:creator>
<dc:creator>Marianna Fontana</dc:creator>
<dc:creator>Marco Canepa</dc:creator>
<dc:creator>Elena Biagini</dc:creator>
<dc:creator>Francesco Cappelli</dc:creator>
<dc:creator>Christian Gagliardi</dc:creator>
<dc:creator>Simone Longhi</dc:creator>
<dc:creator>Linda Pagura</dc:creator>
<dc:creator>Giacomo Tini</dc:creator>
<dc:creator>Franca Dore</dc:creator>
<dc:creator>Rachele Bonfiglioli</dc:creator>
<dc:creator>Matteo Bauckneht</dc:creator>
<dc:creator>Alberto Miceli</dc:creator>
<dc:creator>Francesca Girardi</dc:creator>
<dc:creator>Anna Lisa Martini</dc:creator>
<dc:creator>Giulia Barbati</dc:creator>
<dc:creator>Egidio Natalino Costanzo</dc:creator>
<dc:creator>Angelo Giuseppe Caponetti</dc:creator>
<dc:creator>Andrea Paccagnella</dc:creator>
<dc:creator>Maurizio Sguazzotti</dc:creator>
<dc:creator>Giovanni La Malfa</dc:creator>
<dc:creator>Mattia Zampieri</dc:creator>
<dc:creator>Roberto Sciagrà</dc:creator>
<dc:creator>Federico Perfetto</dc:creator>
<dc:creator>Dorota Rowczenio</dc:creator>
<dc:creator>Janet Gilbertson</dc:creator>
<dc:creator>David F Hutt</dc:creator>
<dc:creator>Philip N Hawkins</dc:creator>
<dc:creator>Claudio Rapezzi</dc:creator>
<dc:creator>Marco Merlo</dc:creator>
<dc:creator>Gianfranco Sinagra</dc:creator>
<dc:creator>Julian D Gillmore</dc:creator>
<dc:date>2024-02-08</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Clinical and Prognostic Implications of Right Ventricular Uptake on Bone Scintigraphy in Transthyretin Amyloid Cardiomyopathy</dc:title>
<dc:identifier>pmid:38328945</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.066524</dc:identifier>
</item>
<item>
<title>Phosphorylation-Regulated Dynamic Phase Separation of HIP-55 Protects Against Heart Failure</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38328928/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240209170828&amp;v=2.18.0
      <description>CONCLUSIONS: Our work reveals that the phosphorylation-regulated dynamic phase separation of HIP-55 protects against sympathetic/adrenergic system-mediated heart failure.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Feb 8. doi: 10.1161/CIRCULATIONAHA.123.067519. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Heart failure (HF), which is the terminal stage of many cardiovascular diseases, is associated with low survival rates and a severe financial burden. The mechanisms, especially the molecular mechanism combined with new theories, underlying the pathogenesis of HF remain elusive. We demonstrate that phosphorylation-regulated dynamic liquid-liquid phase separation of HIP-55 (hematopoietic progenitor kinase 1-interacting protein of 55 kDa) protects against HF.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Fluorescence recovery after photobleaching assay, differential interference contrast analysis, pull-down assay, immunofluorescence, and immunohistochemical analysis were used to investigate the liquid-liquid phase separation capacity of HIP-55 and its dynamic regulation in vivo and in vitro. Mice with genetic deletion of HIP-55 and mice with cardiac-specific overexpression of HIP-55 were used to examine the role of HIP-55 on β-adrenergic receptor hyperactivation-induced HF. Mutation analysis and mice with specific phospho-resistant site mutagenesis were used to identify the role of phosphorylation-regulated dynamic liquid-liquid phase separation of HIP-55 in HF.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Genetic deletion of HIP-55 aggravated HF, whereas cardiac-specific overexpression of HIP-55 significantly alleviated HF in vivo. HIP-55 possesses a strong capacity for phase separation. Phase separation of HIP-55 is dynamically regulated by AKT-mediated phosphorylation at S269 and T291 sites, failure of which leads to impairment of HIP-55 dynamic phase separation by formation of abnormal aggregation. Prolonged sympathetic hyperactivation stress induced decreased phosphorylation of HIP-55 S269 and T291, dysregulated phase separation, and subsequent aggregate formation of HIP55. Moreover, we demonstrated the important role of dynamic phase separation of HIP-55 in inhibiting hyperactivation of the β-adrenergic receptor-mediated P38/MAPK (mitogen-activated protein kinase) signaling pathway. A phosphorylation-deficient HIP-55 mutation, which undergoes massive phase separation and forms insoluble aggregates, loses the protective activity against HF.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Our work reveals that the phosphorylation-regulated dynamic phase separation of HIP-55 protects against sympathetic/adrenergic system-mediated heart failure.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38328928/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240209170828&v=2.18.0">38328928</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.067519>10.1161/CIRCULATIONAHA.123.067519</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38328928</guid>
<pubDate>Thu, 08 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Yunqi Jiang</dc:creator>
<dc:creator>Jinge Gu</dc:creator>
<dc:creator>Xiaodou Niu</dc:creator>
<dc:creator>Jiaojiao Hu</dc:creator>
<dc:creator>Yongzhen Zhang</dc:creator>
<dc:creator>Dan Li</dc:creator>
<dc:creator>Yida Tang</dc:creator>
<dc:creator>Cong Liu</dc:creator>
<dc:creator>Zijian Li</dc:creator>
<dc:date>2024-02-08</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Phosphorylation-Regulated Dynamic Phase Separation of HIP-55 Protects Against Heart Failure</dc:title>
<dc:identifier>pmid:38328928</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.067519</dc:identifier>
</item>
<item>
<title>Transcatheter mitral valve replacement at an inflection point: lessons learned and the path forward</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38327011/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240209170828&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Feb 8:ehae013. doi: 10.1093/eurheartj/ehae013. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38327011/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240209170828&v=2.18.0">38327011</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae013>10.1093/eurheartj/ehae013</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38327011</guid>
<pubDate>Thu, 08 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Sebastian Ludwig</dc:creator>
<dc:creator>Juan F Granada</dc:creator>
<dc:date>2024-02-08</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Transcatheter mitral valve replacement at an inflection point: lessons learned and the path forward</dc:title>
<dc:identifier>pmid:38327011</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae013</dc:identifier>
</item>
<item>
<title>Digital technology and artificial intelligence for improving congenital heart disease care: alea iacta est</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38327005/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240209170828&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Feb 8:ehad898. doi: 10.1093/eurheartj/ehad898. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38327005/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240209170828&v=2.18.0">38327005</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad898>10.1093/eurheartj/ehad898</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38327005</guid>
<pubDate>Thu, 08 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Charo Bruce</dc:creator>
<dc:creator>Michael A Gatzoulis</dc:creator>
<dc:creator>Margarita Brida</dc:creator>
<dc:date>2024-02-08</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Digital technology and artificial intelligence for improving congenital heart disease care: alea iacta est</dc:title>
<dc:identifier>pmid:38327005</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad898</dc:identifier>
</item>
<item>
<title>Hypertension and the kidney: an update</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38326985/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240209170828&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Feb 8:ehad896. doi: 10.1093/eurheartj/ehad896. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38326985/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240209170828&v=2.18.0">38326985</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad896>10.1093/eurheartj/ehad896</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38326985</guid>
<pubDate>Thu, 08 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Luis M Ruilope</dc:creator>
<dc:creator>Alberto Ortiz</dc:creator>
<dc:creator>Gema Ruiz-Hurtado</dc:creator>
<dc:date>2024-02-08</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Hypertension and the kidney: an update</dc:title>
<dc:identifier>pmid:38326985</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad896</dc:identifier>
</item>
<item>
<title>Iron deficiency and supplementation in heart failure</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38326440/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240209170828&amp;v=2.18.0
      <description>Non-anaemic iron deficiency (NAID) is a strategic target in cardiovascular medicine because of its association with a range of adverse effects in various conditions. Endeavours to tackle NAID in heart failure have yielded mixed results, exposing knowledge gaps in how best to define 'iron deficiency' and the handling of iron therapies by the body. To address these gaps, we harness the latest understanding of the mechanisms of iron homeostasis outside the erythron and integrate clinical and...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2024 Feb 7. doi: 10.1038/s41569-024-00988-1. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Non-anaemic iron deficiency (NAID) is a strategic target in cardiovascular medicine because of its association with a range of adverse effects in various conditions. Endeavours to tackle NAID in heart failure have yielded mixed results, exposing knowledge gaps in how best to define 'iron deficiency' and the handling of iron therapies by the body. To address these gaps, we harness the latest understanding of the mechanisms of iron homeostasis outside the erythron and integrate clinical and preclinical lines of evidence. The emerging picture is that current definitions of iron deficiency do not assimilate the multiple influences at play in patients with heart failure and, consequently, fail to identify those with a truly unmet need for iron. Additionally, current iron supplementation therapies benefit only certain patients with heart failure, reflecting differences in the nature of the unmet need for iron and the modifying effects of anaemia and inflammation on the handling of iron therapies by the body. Building on these insights, we identify untapped opportunities in the management of NAID, including the refinement of current approaches and the development of novel strategies. Lessons learned from NAID in cardiovascular disease could ultimately translate into benefits for patients with other chronic conditions such as chronic kidney disease, chronic obstructive pulmonary disease and cancer.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38326440/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240209170828&v=2.18.0">38326440</a> | DOI:<a href=https://doi.org/10.1038/s41569-024-00988-1>10.1038/s41569-024-00988-1</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38326440</guid>
<pubDate>Wed, 07 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Samira Lakhal-Littleton</dc:creator>
<dc:creator>John G F Cleland</dc:creator>
<dc:date>2024-02-07</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Iron deficiency and supplementation in heart failure</dc:title>
<dc:identifier>pmid:38326440</dc:identifier>
<dc:identifier>doi:10.1038/s41569-024-00988-1</dc:identifier>
</item>
<item>
<title>DYRK1A gene linked to heart defects in Down syndrome</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38326439/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240209170828&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2024 Feb 7. doi: 10.1038/s41569-024-00995-2. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38326439/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240209170828&v=2.18.0">38326439</a> | DOI:<a href=https://doi.org/10.1038/s41569-024-00995-2>10.1038/s41569-024-00995-2</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38326439</guid>
<pubDate>Wed, 07 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Irene Fernández-Ruiz</dc:creator>
<dc:date>2024-02-07</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>DYRK1A gene linked to heart defects in Down syndrome</dc:title>
<dc:identifier>pmid:38326439</dc:identifier>
<dc:identifier>doi:10.1038/s41569-024-00995-2</dc:identifier>
</item>
<item>
<title>Reply: miRNAs, PICP, and Extent of Cardiac Damage in Patients With Fabry Disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38325998/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240209170828&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Feb 13;83(6):e59. doi: 10.1016/j.jacc.2023.11.031.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38325998/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240209170828&v=2.18.0">38325998</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.11.031>10.1016/j.jacc.2023.11.031</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38325998</guid>
<pubDate>Wed, 07 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Maria Chiara Meucci</dc:creator>
<dc:creator>Rosa Lillo</dc:creator>
<dc:creator>Francesca Graziani</dc:creator>
<dc:date>2024-02-07</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Reply: miRNAs, PICP, and Extent of Cardiac Damage in Patients With Fabry Disease</dc:title>
<dc:identifier>pmid:38325998</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.11.031</dc:identifier>
</item>
<item>
<title>miRNAs, PICP, and Extent of Cardiac Damage in Patients With Fabry Disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38325997/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240209170828&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Feb 13;83(6):e57. doi: 10.1016/j.jacc.2023.10.052.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38325997/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240209170828&v=2.18.0">38325997</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.10.052>10.1016/j.jacc.2023.10.052</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38325997</guid>
<pubDate>Wed, 07 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Salvatore Patanè</dc:creator>
<dc:creator>Roberto Licordari</dc:creator>
<dc:date>2024-02-07</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>miRNAs, PICP, and Extent of Cardiac Damage in Patients With Fabry Disease</dc:title>
<dc:identifier>pmid:38325997</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.10.052</dc:identifier>
</item>
<item>
<title>Measuring Absolute Coronary Flow and Microvascular Resistance by Thermodilution: JACC Review Topic of the Week</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38325996/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240209170828&amp;v=2.18.0
      <description>Diagnosing coronary microvascular dysfunction remains challenging, primarily due to the lack of direct measurements of absolute coronary blood flow (Q) and microvascular resistance (R(μ)). However, there has been recent progress with the development and validation of continuous intracoronary thermodilution, which offers a simplified and validated approach for clinical use. This technique enables direct quantification of Q and R(μ), leading to precise and accurate evaluation of the coronary...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Feb 13;83(6):699-709. doi: 10.1016/j.jacc.2023.12.014.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Diagnosing coronary microvascular dysfunction remains challenging, primarily due to the lack of direct measurements of absolute coronary blood flow (Q) and microvascular resistance (R<sub>μ</sub>). However, there has been recent progress with the development and validation of continuous intracoronary thermodilution, which offers a simplified and validated approach for clinical use. This technique enables direct quantification of Q and R<sub>μ</sub>, leading to precise and accurate evaluation of the coronary microcirculation. To ensure consistent and reliable results, it is crucial to follow a standardized protocol when performing continuous intracoronary thermodilution measurements. This document aims to summarize the principles of thermodilution-derived absolute coronary flow measurements and propose a standardized method for conducting these assessments. The proposed standardization serves as a guide to ensure the best practice of the method, enhancing the clinical assessment of the coronary microcirculation.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38325996/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240209170828&v=2.18.0">38325996</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.12.014>10.1016/j.jacc.2023.12.014</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38325996</guid>
<pubDate>Wed, 07 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Marta Belmonte</dc:creator>
<dc:creator>Emanuele Gallinoro</dc:creator>
<dc:creator>Nico H J Pijls</dc:creator>
<dc:creator>Dario Tino Bertolone</dc:creator>
<dc:creator>Danielle C J Keulards</dc:creator>
<dc:creator>Michele Mattia Viscusi</dc:creator>
<dc:creator>Tatyana Storozhenko</dc:creator>
<dc:creator>Takuya Mizukami</dc:creator>
<dc:creator>Thabo Mahendiran</dc:creator>
<dc:creator>Ruiko Seki</dc:creator>
<dc:creator>Stephane Fournier</dc:creator>
<dc:creator>Annemiek de Vos</dc:creator>
<dc:creator>Julien Adjedj</dc:creator>
<dc:creator>Emanuele Barbato</dc:creator>
<dc:creator>Jeroen Sonck</dc:creator>
<dc:creator>Peter Damman</dc:creator>
<dc:creator>Thomas Keeble</dc:creator>
<dc:creator>Samer Fawaz</dc:creator>
<dc:creator>Alejandro Gutiérrez-Barrios</dc:creator>
<dc:creator>Valeria Paradies</dc:creator>
<dc:creator>Frederic Bouisset</dc:creator>
<dc:creator>Morton J Kern</dc:creator>
<dc:creator>William F Fearon</dc:creator>
<dc:creator>Carlos Collet</dc:creator>
<dc:creator>Bernard De Bruyne</dc:creator>
<dc:date>2024-02-07</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Measuring Absolute Coronary Flow and Microvascular Resistance by Thermodilution: JACC Review Topic of the Week</dc:title>
<dc:identifier>pmid:38325996</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.12.014</dc:identifier>
</item>
<item>
<title>Implantable Hemodynamic-GUIDE Monitors: A CHAMPION Among Devices for Heart Failure</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38325995/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240209170828&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Feb 13;83(6):695-698. doi: 10.1016/j.jacc.2023.12.008.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38325995/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240209170828&v=2.18.0">38325995</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.12.008>10.1016/j.jacc.2023.12.008</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38325995</guid>
<pubDate>Wed, 07 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Marat Fudim</dc:creator>
<dc:creator>Javed Butler</dc:creator>
<dc:creator>Veraprapas Kittipibul</dc:creator>
<dc:date>2024-02-07</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Implantable Hemodynamic-GUIDE Monitors: A CHAMPION Among Devices for Heart Failure</dc:title>
<dc:identifier>pmid:38325995</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.12.008</dc:identifier>
</item>
<item>
<title>Implantable Hemodynamic Monitors Improve Survival in Patients With Heart Failure and Reduced Ejection Fraction</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38325994/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240209170828&amp;v=2.18.0
      <description>CONCLUSIONS: Management of patients with HFrEF using an implantable hemodynamic monitor significantly reduces both mortality and HF hospitalizations. The reduction in HF hospitalizations is seen early in the first year of monitoring and mortality benefits occur after the first year.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Feb 13;83(6):682-694. doi: 10.1016/j.jacc.2023.11.030.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Trials evaluating implantable hemodynamic monitors to manage patients with heart failure (HF) have shown reductions in HF hospitalizations but not mortality. Prior meta-analyses assessing mortality have been limited in construct because of an absence of patient-level data, short-term follow-up duration, and evaluation across the combined spectrum of ejection fractions.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: The purpose of this meta-analysis was to determine whether management with implantable hemodynamic monitors reduces mortality in patients with heart failure and reduced ejection fraction (HFrEF) and to confirm the effect of hemodynamic-monitoring guided management on HF hospitalization reduction reported in previous studies.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: The patient-level pooled meta-analysis used 3 randomized studies (GUIDE-HF [Hemodynamic-Guided Management of Heart Failure], CHAMPION [CardioMEMS Heart Sensor Allows Monitoring of Pressure to Improve Outcomes in NYHA Class III Heart Failure Patients], and LAPTOP-HF [Left Atrial Pressure Monitoring to Optimize Heart Failure Therapy]) of implantable hemodynamic monitors (2 measuring pulmonary artery pressures and 1 measuring left atrial pressure) to assess the effect on all-cause mortality and HF hospitalizations.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A total of 1,350 patients with HFrEF were included. Hemodynamic-monitoring guided management significantly reduced overall mortality with an HR of 0.75 (95% CI: 0.57-0.99); P = 0.043. HF hospitalizations were significantly reduced with an HR of 0.64 (95% CI: 0.55-0.76); P &lt; 0.0001.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Management of patients with HFrEF using an implantable hemodynamic monitor significantly reduces both mortality and HF hospitalizations. The reduction in HF hospitalizations is seen early in the first year of monitoring and mortality benefits occur after the first year.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38325994/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240209170828&v=2.18.0">38325994</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.11.030>10.1016/j.jacc.2023.11.030</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38325994</guid>
<pubDate>Wed, 07 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>JoAnn Lindenfeld</dc:creator>
<dc:creator>Maria Rosa Costanzo</dc:creator>
<dc:creator>Michael R Zile</dc:creator>
<dc:creator>Anique Ducharme</dc:creator>
<dc:creator>Richard Troughton</dc:creator>
<dc:creator>Alan Maisel</dc:creator>
<dc:creator>Mandeep R Mehra</dc:creator>
<dc:creator>Sara Paul</dc:creator>
<dc:creator>Samuel F Sears</dc:creator>
<dc:creator>Frank Smart</dc:creator>
<dc:creator>Nessa Johnson</dc:creator>
<dc:creator>John Henderson</dc:creator>
<dc:creator>Philip B Adamson</dc:creator>
<dc:creator>Akshay S Desai</dc:creator>
<dc:creator>William T Abraham</dc:creator>
<dc:creator>GUIDE-HF, CHAMPION, and LAPTOP-HF Investigators</dc:creator>
<dc:date>2024-02-07</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Implantable Hemodynamic Monitors Improve Survival in Patients With Heart Failure and Reduced Ejection Fraction</dc:title>
<dc:identifier>pmid:38325994</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.11.030</dc:identifier>
</item>
<item>
<title>Thrombosis, Bleeding, and the Promise of Factor XI(a) Inhibition</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38325993/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240209170828&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Feb 13;83(6):679-681. doi: 10.1016/j.jacc.2023.12.003.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38325993/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240209170828&v=2.18.0">38325993</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.12.003>10.1016/j.jacc.2023.12.003</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38325993</guid>
<pubDate>Wed, 07 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Felicita Andreotti</dc:creator>
<dc:creator>Massimo Massetti</dc:creator>
<dc:creator>Gilles Montalescot</dc:creator>
<dc:date>2024-02-07</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Thrombosis, Bleeding, and the Promise of Factor XI(a) Inhibition</dc:title>
<dc:identifier>pmid:38325993</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.12.003</dc:identifier>
</item>
<item>
<title>Bleeding Outcomes in Patients Treated With Asundexian in Phase II Trials</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38325992/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240209170828&amp;v=2.18.0
      <description>CONCLUSIONS: Analyses of phase II trials involving >;500 bleeds highlight the potential for improved safety of asundexian compared with apixaban and similar safety compared with placebo. Further evidence on the efficacy of asundexian awaits the results of ongoing phase III trials.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Feb 13;83(6):669-678. doi: 10.1016/j.jacc.2023.12.004.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Phase II trials of asundexian were underpowered to detect important differences in bleeding.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: The goal of this study was to obtain best estimates of effects of asundexian vs active control/placebo on major and clinically relevant nonmajor (CRNM) and all bleeding, describe most common sites of bleeding, and explore association between asundexian exposure and bleeding.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We performed a pooled analysis of 3 phase II trials of asundexian in patients with atrial fibrillation (AF), recent acute myocardial infarction (AMI), or stroke. Bleeding was defined according to the International Society on Thrombosis and Hemostasis (ISTH) criteria.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: In patients with AF (n = 755), both asundexian 20 mg and 50 mg once daily vs apixaban had fewer major/CRNM events (3 of 249; incidence rate [IR] per 100 patient-years 5.47 vs 1 of 254 [IR: not calculable] vs 6 of 250 [IR: 11.10]) and all bleeding (12 of 249 [IR: 22.26] vs 10 of 254 [IR: 18.21] vs 26 of 250 [IR: 50.56]). In patients with recent AMI or stroke (n = 3,409), asundexian 10 mg, 20 mg, and 50 mg once daily compared with placebo had similar rates of major/CRNM events (44 of 840 [IR: 7.55] vs 42 of 843 [IR: 7.04] vs 56 of 845 [IR: 9.63] vs 41 of 851 [IR: 6.99]) and all bleeding (107 of 840 [IR: 19.57] vs 123 of 843 [IR: 22.45] vs 130 of 845 [IR: 24.19] vs 129 of 851 [IR: 23.84]). Most common sites of major/CRNM bleeding with asundexian were gastrointestinal, respiratory, urogenital, and skin. There was no significant association between asundexian exposure and major/CRNM bleeding.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Analyses of phase II trials involving >;500 bleeds highlight the potential for improved safety of asundexian compared with apixaban and similar safety compared with placebo. Further evidence on the efficacy of asundexian awaits the results of ongoing phase III trials.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38325992/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240209170828&v=2.18.0">38325992</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.12.004>10.1016/j.jacc.2023.12.004</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38325992</guid>
<pubDate>Wed, 07 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>John W Eikelboom</dc:creator>
<dc:creator>Hardi Mundl</dc:creator>
<dc:creator>John H Alexander</dc:creator>
<dc:creator>Valeria Caso</dc:creator>
<dc:creator>Stuart J Connolly</dc:creator>
<dc:creator>Rosa Coppolecchia</dc:creator>
<dc:creator>Martin Gebel</dc:creator>
<dc:creator>Robert G Hart</dc:creator>
<dc:creator>Gerlind Holberg</dc:creator>
<dc:creator>Lars Keller</dc:creator>
<dc:creator>Manesh R Patel</dc:creator>
<dc:creator>Jonathan P Piccini</dc:creator>
<dc:creator>Sunil V Rao</dc:creator>
<dc:creator>Ashkan Shoamanesh</dc:creator>
<dc:creator>Miriam Tamm</dc:creator>
<dc:creator>Thomas Viethen</dc:creator>
<dc:creator>Ashraf Yassen</dc:creator>
<dc:creator>Marc P Bonaca</dc:creator>
<dc:date>2024-02-07</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Bleeding Outcomes in Patients Treated With Asundexian in Phase II Trials</dc:title>
<dc:identifier>pmid:38325992</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.12.004</dc:identifier>
</item>
<item>
<title>LDL-C Lowering in Prevention of Atherosclerotic Cardiovascular Disease: Another Step Forward in This Lifelong Marathon</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38325991/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240209170828&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Feb 13;83(6):665-668. doi: 10.1016/j.jacc.2023.12.002.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38325991/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240209170828&v=2.18.0">38325991</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.12.002>10.1016/j.jacc.2023.12.002</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38325991</guid>
<pubDate>Wed, 07 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Vijay Nambi</dc:creator>
<dc:creator>Layla A Abushamat</dc:creator>
<dc:date>2024-02-07</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>LDL-C Lowering in Prevention of Atherosclerotic Cardiovascular Disease: Another Step Forward in This Lifelong Marathon</dc:title>
<dc:identifier>pmid:38325991</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.12.002</dc:identifier>
</item>
<item>
<title>Long-Term Efficacy of Evolocumab in Patients With or Without Multivessel Coronary Disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38325990/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240209170828&amp;v=2.18.0
      <description>CONCLUSIONS: Evolocumab reduced the rate of major adverse cardiovascular event in patients with and without MVD. The benefit tended to occur earlier and was larger in patients with MVD. However, the magnitude grew over time in both groups. These data support early initiation of intensive low-density lipoprotein cholesterol lowering both in patients with and without MVD.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Feb 13;83(6):652-664. doi: 10.1016/j.jacc.2023.11.029.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: In FOURIER (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk), during a median follow-up of 2.2 years, risk reduction for major adverse cardiovascular event with evolocumab was greater in patients with multivessel disease (MVD). The FOURIER Open-Label Extension (FOURIER-OLE) provides an additional median follow-up of 5 years.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: The purpose of this study was to assess the long-term benefit of evolocumab in patients with and without MVD.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: FOURIER randomized 27,564 patients to evolocumab vs placebo; 6,635 entered FOURIER-OLE. Patients with coronary artery disease were categorized based on the presence of MVD (≥40% stenosis in ≥2 large vessels). The primary endpoint was cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization; the key secondary endpoint was cardiovascular death, myocardial infarction, or stroke.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Of 23,656 patients in FOURIER with coronary artery disease, 25.4% had MVD; 5,887 patients continued into FOURIER-OLE. The risk reduction with initial allocation to evolocumab tended to be greater in patients with MVD than in those without: 23% (HR: 0.77 [95% CI: 0.68-0.87]) vs 11% (HR: 0.89 [95% CI: 0.82-0.96]) for the primary and 31% (HR: 0.69 [95% CI: 0.59-0.81]) vs 15% (HR: 0.85 [95% CI: 0.77-0.94]) for the key secondary endpoints (P<sub>interaction</sub> = 0.062 and P<sub>interaction</sub> = 0.031, respectively). The magnitude of benefit tended to grow during the first several years, reaching 37% to 38% reductions in risk in patients with MVD and 23% to 28% reductions in risk in patients without MVD.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Evolocumab reduced the rate of major adverse cardiovascular event in patients with and without MVD. The benefit tended to occur earlier and was larger in patients with MVD. However, the magnitude grew over time in both groups. These data support early initiation of intensive low-density lipoprotein cholesterol lowering both in patients with and without MVD.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38325990/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240209170828&v=2.18.0">38325990</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.11.029>10.1016/j.jacc.2023.11.029</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38325990</guid>
<pubDate>Wed, 07 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Daniel J McClintick</dc:creator>
<dc:creator>Michelle L O'Donoghue</dc:creator>
<dc:creator>Gaetano M De Ferrari</dc:creator>
<dc:creator>Jorge Ferreira</dc:creator>
<dc:creator>Xinhui Ran</dc:creator>
<dc:creator>KyungAh Im</dc:creator>
<dc:creator>J Antonio G López</dc:creator>
<dc:creator>Mary Elliott-Davey</dc:creator>
<dc:creator>Bei Wang</dc:creator>
<dc:creator>Maria Laura Monsalvo</dc:creator>
<dc:creator>Dan Atar</dc:creator>
<dc:creator>Anthony Keech</dc:creator>
<dc:creator>Robert P Giugliano</dc:creator>
<dc:creator>Marc S Sabatine</dc:creator>
<dc:date>2024-02-07</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Long-Term Efficacy of Evolocumab in Patients With or Without Multivessel Coronary Disease</dc:title>
<dc:identifier>pmid:38325990</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.11.029</dc:identifier>
</item>
<item>
<title>Bariatric Surgery for Obesity Hypertension: A Gateway for Durable Blood Pressure Control</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38325989/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240209170828&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Feb 13;83(6):649-651. doi: 10.1016/j.jacc.2023.11.033.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38325989/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240209170828&v=2.18.0">38325989</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.11.033>10.1016/j.jacc.2023.11.033</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38325989</guid>
<pubDate>Wed, 07 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Michael E Hall</dc:creator>
<dc:creator>Hunter P Mace</dc:creator>
<dc:creator>John E Hall</dc:creator>
<dc:date>2024-02-07</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Bariatric Surgery for Obesity Hypertension: A Gateway for Durable Blood Pressure Control</dc:title>
<dc:identifier>pmid:38325989</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.11.033</dc:identifier>
</item>
<item>
<title>Randomized Trial of Effect of Bariatric Surgery on Blood Pressure After 5 Years</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38325988/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240209170828&amp;v=2.18.0
      <description>CONCLUSIONS: Bariatric surgery represents an effective and durable strategy to control hypertension and related polypharmacy in subjects with obesity. (GAstric bypass to Treat obEse Patients With steAdy hYpertension [GATEWAY]; NCT01784848).</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Feb 13;83(6):637-648. doi: 10.1016/j.jacc.2023.11.032.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Obesity represents a major obstacle for controlling hypertension, the leading risk factor for cardiovascular mortality.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: The purpose of this study was to determine the long-term effects of bariatric surgery on hypertension control and remission.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We conducted a randomized clinical trial with subjects with obesity grade 1 or 2 plus hypertension using at least 2 medications. We excluded subjects with previous cardiovascular events and poorly controlled type 2 diabetes. Subjects were assigned to Roux-en-Y gastric bypass (RYGB) combined with medical therapy (MT) or MT alone. We reassessed the original primary outcome (reduction of at least 30% of the total antihypertensive medications while maintaining blood pressure levels &lt;140/90 mm Hg) at 5 years. The main analysis followed the intention-to-treat principle.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A total of 100 subjects were included (76% women, age 43.8 ± 9.2 years, body mass index: 36.9 ± 2.7 kg/m<sup>2</sup>). At 5 years, body mass index was 36.40 kg/m<sup>2</sup> (95% CI: 35.28-37.52 kg/m<sup>2</sup>) for MT and 28.01 kg/m<sup>2</sup> (95% CI: 26.95-29.08 kg/m<sup>2</sup>) for RYGB (P &lt; 0.001). Compared with MT, RYGB promoted a significantly higher rate of number of medications reduction (80.7% vs 13.7%; relative risk: 5.91; 95% CI: 2.58-13.52; P &lt; 0.001) and the mean number of antihypertensive medications was 2.97 (95% CI: 2.33-3.60) for MT and 0.80 (95% CI: 0.51-1.09) for RYGB (P &lt; 0.001). The rates of hypertension remission were 2.4% vs 46.9% (relative risk: 19.66; 95% CI: 2.74-141.09; P &lt; 0.001). Sensitivity analysis considering only completed cases revealed consistent results. Interestingly, the rate of apparent resistant hypertension was lower after RYGB (0% vs 15.2%).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Bariatric surgery represents an effective and durable strategy to control hypertension and related polypharmacy in subjects with obesity. (GAstric bypass to Treat obEse Patients With steAdy hYpertension [GATEWAY]; NCT01784848).</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38325988/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240209170828&v=2.18.0">38325988</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.11.032>10.1016/j.jacc.2023.11.032</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38325988</guid>
<pubDate>Wed, 07 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Carlos A Schiavon</dc:creator>
<dc:creator>Alexandre B Cavalcanti</dc:creator>
<dc:creator>Juliana D Oliveira</dc:creator>
<dc:creator>Rachel H V Machado</dc:creator>
<dc:creator>Eliana V Santucci</dc:creator>
<dc:creator>Renato N Santos</dc:creator>
<dc:creator>Julia S Oliveira</dc:creator>
<dc:creator>Lucas P Damiani</dc:creator>
<dc:creator>Débora Junqueira</dc:creator>
<dc:creator>Helio Halpern</dc:creator>
<dc:creator>Frederico de L J Monteiro</dc:creator>
<dc:creator>Patricia M Noujaim</dc:creator>
<dc:creator>Ricardo V Cohen</dc:creator>
<dc:creator>Marcio G de Sousa</dc:creator>
<dc:creator>Luiz A Bortolotto</dc:creator>
<dc:creator>Otavio Berwanger</dc:creator>
<dc:creator>Luciano F Drager</dc:creator>
<dc:date>2024-02-07</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Randomized Trial of Effect of Bariatric Surgery on Blood Pressure After 5 Years</dc:title>
<dc:identifier>pmid:38325988</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.11.032</dc:identifier>
</item>
<item>
<title>An atlas of protein homo-oligomerization across domains of life</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38325366/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240209170828&amp;v=2.18.0
      <description>Protein structures are essential to understanding cellular processes in molecular detail. While advances in artificial intelligence revealed the tertiary structure of proteins at scale, their quaternary structure remains mostly unknown. We devise a scalable strategy based on AlphaFold2 to predict homo-oligomeric assemblies across four proteomes spanning the tree of life. Our results suggest that approximately 45% of an archaeal proteome and a bacterial proteome and 20% of two eukaryotic...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Jan 30:S0092-8674(24)00059-X. doi: 10.1016/j.cell.2024.01.022. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Protein structures are essential to understanding cellular processes in molecular detail. While advances in artificial intelligence revealed the tertiary structure of proteins at scale, their quaternary structure remains mostly unknown. We devise a scalable strategy based on AlphaFold2 to predict homo-oligomeric assemblies across four proteomes spanning the tree of life. Our results suggest that approximately 45% of an archaeal proteome and a bacterial proteome and 20% of two eukaryotic proteomes form homomers. Our predictions accurately capture protein homo-oligomerization, recapitulate megadalton complexes, and unveil hundreds of homo-oligomer types, including three confirmed experimentally by structure determination. Integrating these datasets with omics information suggests that a majority of known protein complexes are symmetric. Finally, these datasets provide a structural context for interpreting disease mutations and reveal coiled-coil regions as major enablers of quaternary structure evolution in human. Our strategy is applicable to any organism and provides a comprehensive view of homo-oligomerization in proteomes.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38325366/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240209170828&v=2.18.0">38325366</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.01.022>10.1016/j.cell.2024.01.022</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38325366</guid>
<pubDate>Wed, 07 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Hugo Schweke</dc:creator>
<dc:creator>Martin Pacesa</dc:creator>
<dc:creator>Tal Levin</dc:creator>
<dc:creator>Casper A Goverde</dc:creator>
<dc:creator>Prasun Kumar</dc:creator>
<dc:creator>Yoan Duhoo</dc:creator>
<dc:creator>Lars J Dornfeld</dc:creator>
<dc:creator>Benjamin Dubreuil</dc:creator>
<dc:creator>Sandrine Georgeon</dc:creator>
<dc:creator>Sergey Ovchinnikov</dc:creator>
<dc:creator>Derek N Woolfson</dc:creator>
<dc:creator>Bruno E Correia</dc:creator>
<dc:creator>Sucharita Dey</dc:creator>
<dc:creator>Emmanuel D Levy</dc:creator>
<dc:date>2024-02-07</dc:date>
<dc:source>Cell</dc:source>
<dc:title>An atlas of protein homo-oligomerization across domains of life</dc:title>
<dc:identifier>pmid:38325366</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.01.022</dc:identifier>
</item>
<item>
<title>The cycling and aging mouse female reproductive tract at single-cell resolution</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38325365/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240209170828&amp;v=2.18.0
      <description>The female reproductive tract (FRT) undergoes extensive remodeling during reproductive cycling. This recurrent remodeling and how it shapes organ-specific aging remains poorly explored. Using single-cell and spatial transcriptomics, we systematically characterized morphological and gene expression changes occurring in ovary, oviduct, uterus, cervix, and vagina at each phase of the mouse estrous cycle, during decidualization, and into aging. These analyses reveal that fibroblasts play central-and...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Jan 31:S0092-8674(24)00058-8. doi: 10.1016/j.cell.2024.01.021. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">The female reproductive tract (FRT) undergoes extensive remodeling during reproductive cycling. This recurrent remodeling and how it shapes organ-specific aging remains poorly explored. Using single-cell and spatial transcriptomics, we systematically characterized morphological and gene expression changes occurring in ovary, oviduct, uterus, cervix, and vagina at each phase of the mouse estrous cycle, during decidualization, and into aging. These analyses reveal that fibroblasts play central-and highly organ-specific-roles in FRT remodeling by orchestrating extracellular matrix (ECM) reorganization and inflammation. Our results suggest a model wherein recurrent FRT remodeling over reproductive lifespan drives the gradual, age-related development of fibrosis and chronic inflammation. This hypothesis was directly tested using chemical ablation of cycling, which reduced fibrotic accumulation during aging. Our atlas provides extensive detail into how estrus, pregnancy, and aging shape the organs of the female reproductive tract and reveals the unexpected cost of the recurrent remodeling required for reproduction.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38325365/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240209170828&v=2.18.0">38325365</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.01.021>10.1016/j.cell.2024.01.021</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38325365</guid>
<pubDate>Wed, 07 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Ivana Winkler</dc:creator>
<dc:creator>Alexander Tolkachov</dc:creator>
<dc:creator>Fritjof Lammers</dc:creator>
<dc:creator>Perrine Lacour</dc:creator>
<dc:creator>Klaudija Daugelaite</dc:creator>
<dc:creator>Nina Schneider</dc:creator>
<dc:creator>Marie-Luise Koch</dc:creator>
<dc:creator>Jasper Panten</dc:creator>
<dc:creator>Florian Grünschläger</dc:creator>
<dc:creator>Tanja Poth</dc:creator>
<dc:creator>Bianca Machado de Ávila</dc:creator>
<dc:creator>Augusto Schneider</dc:creator>
<dc:creator>Simon Haas</dc:creator>
<dc:creator>Duncan T Odom</dc:creator>
<dc:creator>Ângela Gonçalves</dc:creator>
<dc:date>2024-02-07</dc:date>
<dc:source>Cell</dc:source>
<dc:title>The cycling and aging mouse female reproductive tract at single-cell resolution</dc:title>
<dc:identifier>pmid:38325365</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.01.021</dc:identifier>
</item>





























</channel>
</rss>